Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Michail

Geriatric Medicine Granada Hills, CA Medical Doctor

NPI 1760879217 CMS profile 3536151

10605 Balboa Blvd, Ste 260, Granada Hills, CA 91344

Open in the dashboard

General payments

$1,431

45 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Michail of Granada Hills, CA is reported in the CMS Open Payments database as having received $1,431 across 45 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $320 7
2024 General $188 8
2023 General $100 4
2022 General $213 4
2021 General $42 2
2020 General $89 4
2019 General $479 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Michail
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to James Michail were reported at $320. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.

Show as a table
Year James Michail Geriatric Medicine median Middle half National median
2019 $479 $96 $28–$339 $163
2020 $89 $99 $28–$262 $114
2021 $42 $94 $27–$318 $132
2022 $213 $103 $34–$338 $149
2023 $100 $109 $39–$320 $160
2024 $188 $125 $36–$371 $164
2025 $320 $120 $37–$350 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $235 3 payments
  2. Amgen Inc. $173 6 payments
  3. Otsuka America Pharmaceutical, Inc. $168 8 payments
  4. AngioDynamics, Inc. $160 1 payment
  5. Cardiovascular Systems Inc. $133 1 payment
  6. Radius Health, Inc. $59 2 payments
  7. Intuitive Surgical, Inc. $56 1 payment
  8. Sun Pharmaceutical Industries Inc. $41 2 payments
  9. Pfizer Inc. $40 2 payments
  10. GlaxoSmithKline, LLC. $39 2 payments
  11. Other $327 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,431 45 payments
Products named General payments · program years 2019–2025
  1. REXULTI $403 11 payments
  2. EVENITY $173 6 payments
  3. Prolia $173 6 payments
  4. AURYON LASER SYSTEM 100-120 VAC $160 1 payment
  5. Peripheral Orbital Atherectomy System $133 1 payment
  6. Tymlos $59 2 payments
  7. Da Vinci Surgical System $56 1 payment
  8. TRELEGY ELLIPTA $39 2 payments
  9. ENTRESTO $38 2 payments
  10. INGREZZA $31 1 payment
  11. Other $339 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 260 drugs

Part D claims

24,274

Median for Geriatric Medicine: 2,306

Drug cost

$1,660,870

Median for Geriatric Medicine: $150,713

Branded share of claims

21.7%

Median for Geriatric Medicine: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,247 $449,877
Entresto Sacubitril/Valsartan Brand 276 $120,469
Librax Chlordiazepoxide/Clidinium Br Brand 15 $67,638
Januvia Sitagliptin Phosphate Brand 144 $47,435
Jardiance Empagliflozin Brand 108 $44,869
Rexulti Brexpiprazole Brand 46 $44,775
Xarelto Rivaroxaban Brand 88 $40,917
Zileuton Er Zileuton Brand 24 $31,367
Tradjenta Linagliptin Brand 65 $24,910
Farxiga Dapagliflozin Propanediol Brand 46 $22,360

The 10 drugs with the highest cost, of 260 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,814 Part D prescribers listed as Geriatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 91 billing codes

Paid by Medicare

$12,690,823

Of which drugs: $11,029,540

Medicare patients

1,300

Average age 79

Services billed

24,442

758 women, 542 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 61%
Arthritis 58%
Heart failure 52%
Ischemic heart disease 50%
Depression 50%
Alzheimer's or dementia 47%
Chronic kidney disease 44%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Complete ft, per square centimeter Q4271 Office 49 5,930 $7,876,039
Carepatch, per square centimeter Q4236 Office 44 3,584 $2,212,171

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $98
$98 46 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

45 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record